DE69636486D1 - Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind. - Google Patents

Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind.

Info

Publication number
DE69636486D1
DE69636486D1 DE69636486T DE69636486T DE69636486D1 DE 69636486 D1 DE69636486 D1 DE 69636486D1 DE 69636486 T DE69636486 T DE 69636486T DE 69636486 T DE69636486 T DE 69636486T DE 69636486 D1 DE69636486 D1 DE 69636486D1
Authority
DE
Germany
Prior art keywords
ocf2
gas emulsions
fluorinated ethers
emulsions stabilized
2ocf3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636486T
Other languages
English (en)
Other versions
DE69636486T2 (de
Inventor
Alexey Kabalnov
Ernest George Schutt
Jeffrey Greg Weers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcor Pharmaceutical Co
Original Assignee
Imcor Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcor Pharmaceutical Co filed Critical Imcor Pharmaceutical Co
Application granted granted Critical
Publication of DE69636486D1 publication Critical patent/DE69636486D1/de
Publication of DE69636486T2 publication Critical patent/DE69636486T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
DE69636486T 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte Ether mit niedrigen Ostwaldkoeffizienten stabilisiert sind Expired - Fee Related DE69636486T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/479,621 US5804162A (en) 1995-06-07 1995-06-07 Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US479621 1995-06-07

Publications (2)

Publication Number Publication Date
DE69636486D1 true DE69636486D1 (de) 2006-10-05
DE69636486T2 DE69636486T2 (de) 2007-05-03

Family

ID=23904745

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69621015T Expired - Fee Related DE69621015T2 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind
DE69636486T Expired - Fee Related DE69636486T2 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte Ether mit niedrigen Ostwaldkoeffizienten stabilisiert sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69621015T Expired - Fee Related DE69621015T2 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind

Country Status (18)

Country Link
US (2) US5804162A (de)
EP (2) EP1174153B1 (de)
JP (1) JP4067116B2 (de)
KR (1) KR100401429B1 (de)
CN (1) CN1087954C (de)
AT (2) ATE337018T1 (de)
AU (1) AU712946B2 (de)
CA (1) CA2222186A1 (de)
CZ (1) CZ391397A3 (de)
DE (2) DE69621015T2 (de)
DK (1) DK0833669T3 (de)
ES (2) ES2176462T3 (de)
HU (1) HUP9900848A3 (de)
IL (1) IL122217A (de)
NO (1) NO975317L (de)
PL (1) PL185883B1 (de)
PT (1) PT833669E (de)
WO (1) WO1996040281A2 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
DK0711179T3 (da) * 1993-07-30 2005-02-14 Imcor Pharmaceutical Co Stabiliserede sammensætninger med mikrobobler til ultralyd
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
ATE345682T1 (de) 1996-05-01 2006-12-15 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
IL128057A (en) * 1996-08-05 2001-08-26 Schering Ag Process for the production of contrast media
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
DE69737915T2 (de) 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
EE03749B1 (et) 1996-10-21 2002-06-17 Nycomed Imaging As Kombineeritud preparaat samaaegseks, eraldi või järjestikuseks kasutamiseks kontrastainena ultrahelikujutamisel
WO1998023298A1 (en) * 1996-11-25 1998-06-04 Imarx Pharmaceutical Corp. Perfluorinated-ether compositions as diagnostic contrast agents
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
EP1982990A1 (de) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Zytokinrezeptor wie eine gemeinsame Gammakette
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6270460B1 (en) * 1999-06-24 2001-08-07 Acuson Corporation Apparatus and method to limit the life span of a diagnostic medical ultrasound probe
EP1276849A4 (de) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusionsproteine
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6849194B2 (en) 2000-11-17 2005-02-01 Pcbu Services, Inc. Methods for preparing ethers, ether compositions, fluoroether fire extinguishing systems, mixtures and methods
EP1683865A3 (de) 2001-02-02 2006-10-25 Eli Lilly & Company Säugerproteine und insbesondere CD200
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
AU2003235791A1 (en) 2002-01-08 2003-07-24 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7300743B2 (en) * 2003-03-06 2007-11-27 E. I. Du Pont De Nemours And Company Radiation durable organic compounds with high transparency in the vacuum ultraviolet, and method for preparing
EP1628992A4 (de) 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic Verfahren zur modulation der metastasierung sowie von metastasen herrührender verwandter ereignisse im skelett
US20050074406A1 (en) * 2003-10-03 2005-04-07 Scimed Life Systems, Inc. Ultrasound coating for enhancing visualization of medical device in ultrasound images
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CA2790675C (en) 2005-07-19 2016-12-20 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
JP5191392B2 (ja) 2005-11-07 2013-05-08 ザ スクリプス リサーチ インスティチュート 組織因子シグナル伝達の特異性を調節するための組成物及び方法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
CA2723171C (en) * 2008-05-02 2018-03-27 Celsense, Inc. Emulsion compositions and methods for nuclear magnetic resonance and other imaging
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US20100160576A1 (en) * 2008-11-21 2010-06-24 University Of Tennessee Research Foundation Perfluorinated poly(oxymethylene) compounds
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
EP2776022A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
JP2013180956A (ja) * 2012-02-29 2013-09-12 Sunstar Engineering Inc 殺菌剤組成物
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
EP2870242A1 (de) 2012-07-05 2015-05-13 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
CN104353088A (zh) * 2014-09-30 2015-02-18 东南大学 一种脂质气泡的制备方法
US10052394B2 (en) 2014-11-21 2018-08-21 General Electric Company Microbubble tether for diagnostic and therapeutic applications
MX2017008721A (es) 2014-12-31 2017-11-17 Lantheus Medical Imaging Inc Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3176206A1 (de) * 2015-12-01 2017-06-07 Evonik Degussa GmbH Verfahren zur herstellung feinzelliger schaumstoffe unter verwendung eines zellalterungshemmers
KR20180133527A (ko) 2016-05-04 2018-12-14 랜티우스 메디컬 이메징, 인크. 초음파 조영제의 제조 방법 및 장치
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11225689B2 (en) 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220143148A1 (en) 2019-03-14 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
WO2024016003A2 (en) 2022-07-14 2024-01-18 The Broad Institute, Inc. Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
WO1982001642A1 (en) * 1980-11-17 1982-05-27 Med Inc Ultra Microbubble precursors and methods for their production and use
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3313947A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3324754A1 (de) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen Ultraschallkontrastmittel sowie dessen herstellung
GB8504916D0 (en) * 1985-02-26 1985-03-27 Isc Chemicals Ltd Emulsions of perfluorocarbons in aqueous media
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4613326A (en) * 1985-07-12 1986-09-23 Becton, Dickinson And Company Two-component medication syringe assembly
DE3529195A1 (de) * 1985-08-14 1987-02-26 Max Planck Gesellschaft Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
DE3688613T2 (de) * 1985-11-18 1994-01-13 Access Pharma Inc Polychelierende stoffe für abbildung- und spektralerhöhung (und spektrale verschiebung).
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0231091B1 (de) * 1986-01-24 1993-03-31 Children's Hospital Medical Center Stabile Emulsionen von stark fluorierten, organischen Verbindungen
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
DE3741201A1 (de) * 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
DE3741199A1 (de) * 1987-12-02 1989-08-17 Schering Ag Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
WO1989006978A1 (en) * 1988-02-05 1989-08-10 Schering Aktiengesellschaft Berlin Und Bergkamen Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
US5556610A (en) * 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (de) * 1990-04-02 1993-05-01 Sint Sa
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
GB9009423D0 (en) * 1990-04-26 1990-06-20 Williams Alun R Assessment of vascular perfusion by the display of harmonic echoes from ultrasonically excited gas bubbles
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5315997A (en) * 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
JP3247374B2 (ja) * 1990-10-05 2002-01-15 ブラッコ インターナショナル ベスローテン フェンノートシャップ 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法
DE4100470A1 (de) * 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
EP0504881B2 (de) * 1991-03-22 2000-11-08 Katsuro Tachibana Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
JP3319754B2 (ja) * 1991-06-03 2002-09-03 ニユコメド・イメージング・アクシエセルカペト 造影剤におけるまたは造影剤に関する改良
ATE151993T1 (de) * 1991-07-05 1997-05-15 Nycomed Imaging As Verbesserungen an kontrastmitteln
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
WO1993003671A1 (en) * 1991-08-13 1993-03-04 Molecular Biosystem, Inc. Method of mri imaging using diamagnetic contrast agents
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
HU218018B (hu) * 1991-09-17 2000-05-28 Sonus Pharmaceuticals Inc. Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására
WO1993006869A1 (en) * 1991-10-04 1993-04-15 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5196183A (en) * 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
DE4219723A1 (de) * 1992-06-13 1993-12-16 Schering Ag Mikropartikel, Verfahren zu deren Herstellung, sowie die Verwendung dieser in der Diagnostik
AU4563093A (en) * 1992-07-03 1994-01-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Echographic contrast agent composition
CA2144749A1 (en) * 1992-09-16 1994-03-31 Jo Klaveness Improvements in or relating to contrast agents
US5314644A (en) * 1992-10-19 1994-05-24 Virginia Polytechnic Institute And State University Microbubble generator
EP0679066A4 (de) * 1992-11-02 1996-04-03 Univ Drexel Tensid-stabilisierte mikroblasenmischungen, verfahren für ihre herstellung und ihre verwendung.
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
WO1994016739A1 (en) * 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
GB9305349D0 (en) * 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
US5333613A (en) * 1993-03-23 1994-08-02 Delineate Microparticles as ultrasonic contrast media
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US5798091A (en) * 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
KR100295173B1 (ko) * 1993-12-15 2001-09-17 엔. 토모브 초음파콘트라스트매질로서유용한가스혼합물
DE4406474A1 (de) * 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5562893A (en) * 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
GB9808599D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or realting to contrast agents
GB9808582D0 (en) * 1998-04-22 1998-06-24 Nycomed Imaging As Improvements in or relating to contrast agents

Also Published As

Publication number Publication date
IL122217A (en) 2002-03-10
EP1174153A3 (de) 2002-07-31
DE69621015T2 (de) 2002-12-19
DK0833669T3 (da) 2002-08-12
DE69636486T2 (de) 2007-05-03
WO1996040281B1 (en) 2001-04-05
KR19990022594A (ko) 1999-03-25
HUP9900848A2 (hu) 1999-07-28
IL122217A0 (en) 1998-04-05
WO1996040281A2 (en) 1996-12-19
CA2222186A1 (en) 1996-12-19
CN1087954C (zh) 2002-07-24
DE69621015D1 (de) 2002-06-06
NO975317D0 (no) 1997-11-19
MX9709564A (es) 1998-10-31
EP1174153A2 (de) 2002-01-23
ATE337018T1 (de) 2006-09-15
US5804162A (en) 1998-09-08
ES2176462T3 (es) 2002-12-01
NO975317L (no) 1998-01-09
CZ391397A3 (cs) 1998-05-13
ES2269262T3 (es) 2007-04-01
AU712946B2 (en) 1999-11-18
PL323868A1 (en) 1998-04-27
KR100401429B1 (ko) 2004-02-18
WO1996040281A3 (en) 1997-03-13
JP4067116B2 (ja) 2008-03-26
EP0833669A2 (de) 1998-04-08
JPH11506782A (ja) 1999-06-15
EP1174153B1 (de) 2006-08-23
HUP9900848A3 (en) 1999-11-29
PT833669E (pt) 2002-09-30
US6193952B1 (en) 2001-02-27
AU6048796A (en) 1996-12-30
EP0833669B1 (de) 2002-05-02
ATE216894T1 (de) 2002-05-15
CN1192159A (zh) 1998-09-02
PL185883B1 (pl) 2003-08-29

Similar Documents

Publication Publication Date Title
DE69636486D1 (de) Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind.
US6075559A (en) Vehicle moving image processing method and system
ATE180170T1 (de) Liposome als kontrastmittel für ultraschallabbildung
WO1992018165A3 (en) Improved fluorocarbon contrast media for use with MRI and radiographic imaging
EP1617674A2 (de) Verlustfreie Codierung eines interessierenden Gebiets
ATE143033T1 (de) Beständige perfluoropolyätheremulsionen
DE69924587D1 (de) Verfahren zur Bildrekonstruktion für Tomographie
NL950010I1 (nl) R¦ntgencontrastmiddelen.
EP1175060A3 (de) Middleware-schicht zwischen Sprachanwendungen und Sprachtreiber
DK0660724T3 (da) Forberinger vedrørende kontrastmidler
DE69403094T2 (de) Lösungsmittelgemisch sowie Reinigungsverfahren die es verwenden
EP0751670A3 (de) Optischer Weg für ein Abtastsystem
AU2002213876A1 (en) A method and a device for objective speech quality assessment without reference signal
ATE232343T1 (de) Gerät zur aufzeichnung eines standbildes, wahlweise zusammen mit einem sprachcodebild, in optisch lesbarer form
DE3855807D1 (de) Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
WO2002058560A3 (en) Compensation for view aliasing artifacts in radiation imaging, in particular in computer tomography
EP1143427A3 (de) Optisches Aufzeichnungsverfahren, optisches Aufzeichnungsgerät und optisches Aufzeichnungsmedium
ES2089020T3 (es) Formulaciones desespumantes/antiespumantes de baja viscosidad.
EP0926678A2 (de) Verfahren und Gerät zum Schneiden-und-Verknüpfen komprimierten Videosegments zur Nachbearbeitung
EP1120974A3 (de) Abtastung gefolgt von einer adaptiven Teilbandkodierung
EP0917350A3 (de) Bildkodierungs- und -aufzeichnungsgerät
CA2110925A1 (en) Polyetheresterols, Their Preparation, and Their Use in Polyurethanes
DE69700560T2 (de) Härtbare Fluorelastomerzusammensetzungen
WO2002077712A3 (en) Photoresist composition
Woods et al. Motion compensated multiresolution transmission of HDTV

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee